Abstract:The chemokines/chemokine receptors pathway significantly influences cell migration, particularly in recruiting immune cells to the tumor microenvironment (TME), impacting tumor progression and treatment outcomes. Emerging research emphasizes the involvement of chemokines in drug resistance across various tumor therapies, including immunotherapy, chemotherapy, and targeted therapy. This review focuses on the role of chemokines/chemokine receptors in pancreatic cancer (PC) development, highlighting their impact on TME remodeling, immunotherapy, and relevant signaling pathways. The unique immunosuppressive microenvironment formed by the interaction of tumor cells, stromal cells and immune cells plays an important role in the tumor proliferation, invasion, migration and therapeutic resistance. Chemokines/chemokine receptors, such as chemokine ligand (CCL) 2, CCL3, CCL5, CCL20, CCL21, C-X-C motif chemokine ligand (CXCL) 1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, and C-X3-C motif chemokine ligand (CX3CL)1, derived mainly from leukocyte cells, cancer-related fibroblasts (CAFs), pancreatic stellate cells (PSCs), and tumor-associated macrophages (TAMs), contribute to PC progression and treatment resistance. Chemokines recruit myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), and M2 macrophages, inhibiting the anti-tumor activity of immune cells. Simultaneously, they enhance pathways like epithelial-mesenchymal transition (EMT), Akt serine/threonine kinase (AKT), extracellular regulated protein kinases (ERK) 1/2, and nuclear factor kappa-B (NF-κB), etc., elevating the risk of PC metastasis and compromising the efficacy of radiotherapy, chemotherapy, and anti-PD-1/PD-L1 immunotherapy. Notably, the CCLx-CCR2 and CXCLx-CXCR2/4 axis emerge as potential therapeutic targets in PC. This review integrates recent findings on chemokines and receptors in PC treatment, offering valuable insights for innovative therapeutic approaches.

Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy

Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

How chemokines organize the tumour microenvironment

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy

Chemokine Systems in Oncology: from Microenvironment Modulation to Nanocarrier Innovations.

Chemokines and Lung Cancer

The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages

Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy

The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment

Chemokines and their role in tumor growth and metastasis

The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment

From Biomarkers to Therapeutic Targets

Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer